Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer

Tianhong Li, Primo N. Lara, Philip C. Mack, Roman Perez-Soler, David R. Gandara

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Both the multi-targeted antifolate pemetrexed and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib have established roles in the treatment of advanced non-small cell lung cancer (NSCLC). Given different mechanisms of action and minimal overlapping toxicities, combinations of these agents have been considered. However, four previous phase III trials investigating concurrent chemotherapy with or without EGFR TKIs showed no clinical benefit. Based on preclinical data, we developed a model of pharmacodynamic separation to avoid potential negative interactions between chemotherapy and EGFR TKIs in NSCLC tumors containing wild-type EGFR gene. This review summarizes the background, scientific rationale and early clinical data in support of intercalation of intermittent erlotinib dosing with pemetrexed as a means of achieving pharmacodynamic separation. Ongoing research efforts investigating this concept are reviewed.

Original languageEnglish (US)
Pages (from-to)85-94
Number of pages10
JournalCurrent Drug Targets
Volume11
Issue number1
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Pemetrexed
Intercalation
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Cells
Pharmacodynamics
Chemotherapy
Folic Acid Antagonists
erbB-1 Genes
Drug Therapy
Protein-Tyrosine Kinases
Therapeutics
Toxicity
Tumors
Genes
Research
Erlotinib Hydrochloride
Neoplasms

Keywords

  • Epidermal growth factor receptor (EGFR)
  • Erlotinib
  • Multi-targeted antifolate
  • Non-small cell lung cancer (NSCLC)
  • Pemetrexed
  • Small molecule tyrosine kinase inhibitor (TKI)

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer. / Li, Tianhong; Lara, Primo N.; Mack, Philip C.; Perez-Soler, Roman; Gandara, David R.

In: Current Drug Targets, Vol. 11, No. 1, 2010, p. 85-94.

Research output: Contribution to journalArticle

Li, Tianhong ; Lara, Primo N. ; Mack, Philip C. ; Perez-Soler, Roman ; Gandara, David R. / Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer. In: Current Drug Targets. 2010 ; Vol. 11, No. 1. pp. 85-94.
@article{c5d6db9c783e41058d18fa195ffde56e,
title = "Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer",
abstract = "Both the multi-targeted antifolate pemetrexed and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib have established roles in the treatment of advanced non-small cell lung cancer (NSCLC). Given different mechanisms of action and minimal overlapping toxicities, combinations of these agents have been considered. However, four previous phase III trials investigating concurrent chemotherapy with or without EGFR TKIs showed no clinical benefit. Based on preclinical data, we developed a model of pharmacodynamic separation to avoid potential negative interactions between chemotherapy and EGFR TKIs in NSCLC tumors containing wild-type EGFR gene. This review summarizes the background, scientific rationale and early clinical data in support of intercalation of intermittent erlotinib dosing with pemetrexed as a means of achieving pharmacodynamic separation. Ongoing research efforts investigating this concept are reviewed.",
keywords = "Epidermal growth factor receptor (EGFR), Erlotinib, Multi-targeted antifolate, Non-small cell lung cancer (NSCLC), Pemetrexed, Small molecule tyrosine kinase inhibitor (TKI)",
author = "Tianhong Li and Lara, {Primo N.} and Mack, {Philip C.} and Roman Perez-Soler and Gandara, {David R.}",
year = "2010",
doi = "10.2174/138945010790030983",
language = "English (US)",
volume = "11",
pages = "85--94",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer

AU - Li, Tianhong

AU - Lara, Primo N.

AU - Mack, Philip C.

AU - Perez-Soler, Roman

AU - Gandara, David R.

PY - 2010

Y1 - 2010

N2 - Both the multi-targeted antifolate pemetrexed and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib have established roles in the treatment of advanced non-small cell lung cancer (NSCLC). Given different mechanisms of action and minimal overlapping toxicities, combinations of these agents have been considered. However, four previous phase III trials investigating concurrent chemotherapy with or without EGFR TKIs showed no clinical benefit. Based on preclinical data, we developed a model of pharmacodynamic separation to avoid potential negative interactions between chemotherapy and EGFR TKIs in NSCLC tumors containing wild-type EGFR gene. This review summarizes the background, scientific rationale and early clinical data in support of intercalation of intermittent erlotinib dosing with pemetrexed as a means of achieving pharmacodynamic separation. Ongoing research efforts investigating this concept are reviewed.

AB - Both the multi-targeted antifolate pemetrexed and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib have established roles in the treatment of advanced non-small cell lung cancer (NSCLC). Given different mechanisms of action and minimal overlapping toxicities, combinations of these agents have been considered. However, four previous phase III trials investigating concurrent chemotherapy with or without EGFR TKIs showed no clinical benefit. Based on preclinical data, we developed a model of pharmacodynamic separation to avoid potential negative interactions between chemotherapy and EGFR TKIs in NSCLC tumors containing wild-type EGFR gene. This review summarizes the background, scientific rationale and early clinical data in support of intercalation of intermittent erlotinib dosing with pemetrexed as a means of achieving pharmacodynamic separation. Ongoing research efforts investigating this concept are reviewed.

KW - Epidermal growth factor receptor (EGFR)

KW - Erlotinib

KW - Multi-targeted antifolate

KW - Non-small cell lung cancer (NSCLC)

KW - Pemetrexed

KW - Small molecule tyrosine kinase inhibitor (TKI)

UR - http://www.scopus.com/inward/record.url?scp=77949465178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949465178&partnerID=8YFLogxK

U2 - 10.2174/138945010790030983

DO - 10.2174/138945010790030983

M3 - Article

C2 - 19839922

AN - SCOPUS:77949465178

VL - 11

SP - 85

EP - 94

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 1

ER -